Sol-Gel Technologies Ltd. (SLGL)
SLGL trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 20-F (us-gaap:Revenues), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1684693/000117891326001552/0001178913-26-001552-index.htm. Net income: SEC 20-F (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | SLGL on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | Israel |
| IPO year | 2018 |
| SEC CIK | 0001684693 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | Israel |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $19.4M |
| Net income | -$6.1M |
| Operating income | -$7.5M |
| Net margin | -31.6% |
| Operating margin | -38.9% |
| Revenue growth | +68.0% |
| Cash | $11.0M |
| Total assets | $29.9M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 9.3× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | States substantial doubt about continuing as a going concern. "These conditions raise substantial doubt regarding our ability to continue as a going concern within one year after the date of this annual report." | 20-F 2026-03-19 |
| Cash and burn | $11.0M cash; operating cash flow $81K a quarter. | Report 2025-12-31 |
| Shares outstanding | 2,786,158 (2025-12-31); 27,857,620 a year earlier; 23,129,469 three years earlier. 1y figure adjusted for split (1-for-10 overall); 3y figure adjusted for split (1-for-10 overall); the newest SEC cover-page count is from 2025-12-31; shares issued since then are not in these figures. | Cover page 2025-12-31 |
| Reverse splits, 3 years | 1; latest 1-for-10 on 2025-05-05 | Source 2025-05-05 |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 1 424B5 takedowns | Latest 2026-03-24 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Kesselman & Kesselman C.P.A.s, Tel-Aviv, Israel | PCAOB Form AP 2026-03-30 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $11.2M, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Annual results
| Fiscal year | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| FY 2025 2025-12-31 | $19.4M | -$6.1M | $322K | $11.0M | No debt tags | $19.4M | 20-F 2026-03-19 |
| FY 2024 2024-12-31 | $11.5M | -$10.6M | -$13.9M | $19.5M | No debt tags | $11.5M | 20-F 2026-03-19 |
| FY 2023 2023-12-31 | $1.6M | -$27.2M | -$17.7M | $7.5M | No debt tags | $1.6M | 20-F 2026-03-19 |
| FY 2022 2022-12-31 | $3.9M | -$14.9M | -$9.5M | $12.4M | No debt tags | $3.9M | 20-F 2025-04-29 |
| FY 2021 2021-12-31 | $31.3M | $3.2M | -$7.7M | $20.1M | No debt tags | $31.3M | 20-F 2024-03-13 |
| FY 2020 2020-12-31 | $8.8M | -$29.3M | -$25.2M | $7.1M | No debt tags | $8.8M | 20-F 2023-03-10 |
| FY 2019 2019-12-31 | $22.9M | -$24.6M | -$22.5M | $9.4M | No debt tags | $22.9M | 20-F/A 2022-04-07 |
| FY 2018 2018-12-31 | $129K | -$32.2M | -$23.5M | $5.3M | No debt tags | $129K | 20-F 2021-03-04 |
From SEC XBRL company facts (annual reports only: 20-F or 40-F). Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2026-03-24 |
| Latest annual report | 20-F | 2026-03-19 |
| Latest quarterly / interim | 6-K | 2026-11-12 |
Source: SEC EDGAR submissions feed, 332 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -9.7% |
| 1 month | -19.3% |
| 3 months | -34.4% |
| Year to date | +30.8% |
| 1 year | +54.9% |
| From 52-week high | -43.7% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| WHWK | Whitehawk Therapeutics Inc. | $3.01 | -1.63% | $177.6M |
| NATR | Nature's Sunshine Products Inc. | $10.56 | +1.93% | $183.0M |
| RNAC | Cartesian Therapeutics Inc. | $6.08 | -4.25% | $185.5M |
| KRRO | Korro Bio Inc. | $12.71 | -6.61% | $174.5M |
| IFRX | InflaRx N.V. | $1.18 | +0.85% | $173.9M |
| ANTX | AN2 Therapeutics Inc. | $4.47 | -1.76% | $169.6M |
| ORMP | Oramed Pharmaceuticals Inc. | $3.90 | +5.12% | $169.6M |
| PYXS | Pyxis Oncology Inc. | $1.41 | -10.76% | $168.6M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier